
Earnings Estimates Moving Higher for Cactus (WHD): Time to Buy?
Cactus, Inc. (WHD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
تابع أحدث الأخبار المالية والاقتصادية وتحديثات الأسواق والتقارير والتحليلات على PipVero.

Cactus, Inc. (WHD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

APO's Q2 results are affected by higher expenses as adjusted net income misses estimates. Higher AUM and revenue growth provide support.

Builders FirstSource faces housing weakness, margin pressure and lower earnings estimates as softer demand and reduced guidance weigh on the investment outlook.

BR's fiscal fourth-quarter earnings and revenues top estimates as recurring revenues, closed sales and GTO profitability strengthen.

Snap Inc (NYSE:SNAP) shares surged 14% following the social media company's second quarter results, after revenue and adjusted earnings came in ahead of Wall Street expectations and the company provided an upbeat outlook for the third quarter. Snap reported revenue of $1.60 billion for the second quarter, above the $1.54 billion analyst consensus, while its net loss of $0.10 per share was narrower than the expected $0.12 loss.

Does Live Oak Bancshares (LOB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Argenx (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Does BJ's Restaurants (BJRI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zebra Technologies tops second-quarter earnings and revenue estimates as broad-based growth and acquisitions fuel sales, prompting higher full-year 2026 guidance.

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

POWL's fiscal Q3 earnings and revenues miss estimates, even as record orders and a $2.4 billion backlog strengthen its outlook.

Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.

The Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter.

Flag Ship Acquisition NASDAQ: ETHZ executives, speaking during a Forum Markets presentation hosted by Force Family Office, outlined a strategy centered on acquiring cash-generating real-world assets while maintaining the option to fractionalize and tokenize those assets as the market develops.